The COVID-19 pandemic accelerated a change that was already underway with regards to the digitisation of biopharma marketing – and the increasing ubiquity of omnichannel.
As the landscape of healthcare changes, so too must the way that we interpret and measure performance and success. This is particularly evident in marketing.
A multichannel marketing approach, together with compelling content, is the ultimate way for pharma to deliver the message in the right way to its customers.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh